Cargando…

Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma

BACKGROUND: There is an increasing amount of reports on IFITM1 (interferon-inducible transmembrane protein 1) in various malignancies. The aim of this study was to examine the expression of IFITM1 and its prognostic significance in gastroesophageal adenocarcinoma. METHODS: Tissue samples were obtain...

Descripción completa

Detalles Bibliográficos
Autores principales: Borg, David, Hedner, Charlotta, Gaber, Alexander, Nodin, Björn, Fristedt, Richard, Jirström, Karin, Eberhard, Jakob, Johnsson, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867989/
https://www.ncbi.nlm.nih.gov/pubmed/27186374
http://dx.doi.org/10.1186/s40364-016-0064-5
_version_ 1782432120153571328
author Borg, David
Hedner, Charlotta
Gaber, Alexander
Nodin, Björn
Fristedt, Richard
Jirström, Karin
Eberhard, Jakob
Johnsson, Anders
author_facet Borg, David
Hedner, Charlotta
Gaber, Alexander
Nodin, Björn
Fristedt, Richard
Jirström, Karin
Eberhard, Jakob
Johnsson, Anders
author_sort Borg, David
collection PubMed
description BACKGROUND: There is an increasing amount of reports on IFITM1 (interferon-inducible transmembrane protein 1) in various malignancies. The aim of this study was to examine the expression of IFITM1 and its prognostic significance in gastroesophageal adenocarcinoma. METHODS: Tissue samples were obtained from a consecutive cohort of 174 patients surgically treated between 2006 and 2010 for gastroesophageal (gastric, gastroesophageal junction and esophageal) adenocarcinoma, not subjected to neoadjuvant therapy. Expression of IFITM1 was examined using immunohistochemistry on tissue microarrays of primary tumors and paired samples of adjacent normal epithelium, intestinal metaplasia and lymph node metastases. RESULTS: Expression of IFITM1 was significantly elevated in primary tumors and lymph node metastases compared to adjacent normal epithelium and intestinal metaplasia, regardless of tumor location. Overexpression of IFITM1 was associated with M0-disease (no distant metastases). In gastric cancer IFITM1 expression was significantly associated with improved TTR (time to recurrence) in Kaplan-Meier analysis and Cox regression, both in the unadjusted analysis (HR 0.33, 95 % CI 0.12-0.88) and in the adjusted analysis (HR 0.32, 95 % CI 0.12-0.87) but there was no significant impact on OS (overall survival). In esophageal adenocarcinoma expression of IFITM1 had no impact on TTR or OS in Kaplan-Meier-analyses, but in the adjusted Cox regression IFITM1 expression had a negative impact on both TTR (HR 3.05, 95 % CI 1.09-8.53) and OS (HR 2.71, 95 % CI 1.11-6.67). CONCLUSIONS: IFITM1 was overexpressed in gastroesophageal adenocarcinoma and associated with M0-disease. In gastric cancer IFITM1 expression had a positive impact on TTR but in esophageal cancer it seemed to have an adverse impact on survival. The reason for the diverging prognostic impact of IFITM1 in esophageal and gastric cancer is unclear and warrants further studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40364-016-0064-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4867989
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48679892016-05-17 Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma Borg, David Hedner, Charlotta Gaber, Alexander Nodin, Björn Fristedt, Richard Jirström, Karin Eberhard, Jakob Johnsson, Anders Biomark Res Research BACKGROUND: There is an increasing amount of reports on IFITM1 (interferon-inducible transmembrane protein 1) in various malignancies. The aim of this study was to examine the expression of IFITM1 and its prognostic significance in gastroesophageal adenocarcinoma. METHODS: Tissue samples were obtained from a consecutive cohort of 174 patients surgically treated between 2006 and 2010 for gastroesophageal (gastric, gastroesophageal junction and esophageal) adenocarcinoma, not subjected to neoadjuvant therapy. Expression of IFITM1 was examined using immunohistochemistry on tissue microarrays of primary tumors and paired samples of adjacent normal epithelium, intestinal metaplasia and lymph node metastases. RESULTS: Expression of IFITM1 was significantly elevated in primary tumors and lymph node metastases compared to adjacent normal epithelium and intestinal metaplasia, regardless of tumor location. Overexpression of IFITM1 was associated with M0-disease (no distant metastases). In gastric cancer IFITM1 expression was significantly associated with improved TTR (time to recurrence) in Kaplan-Meier analysis and Cox regression, both in the unadjusted analysis (HR 0.33, 95 % CI 0.12-0.88) and in the adjusted analysis (HR 0.32, 95 % CI 0.12-0.87) but there was no significant impact on OS (overall survival). In esophageal adenocarcinoma expression of IFITM1 had no impact on TTR or OS in Kaplan-Meier-analyses, but in the adjusted Cox regression IFITM1 expression had a negative impact on both TTR (HR 3.05, 95 % CI 1.09-8.53) and OS (HR 2.71, 95 % CI 1.11-6.67). CONCLUSIONS: IFITM1 was overexpressed in gastroesophageal adenocarcinoma and associated with M0-disease. In gastric cancer IFITM1 expression had a positive impact on TTR but in esophageal cancer it seemed to have an adverse impact on survival. The reason for the diverging prognostic impact of IFITM1 in esophageal and gastric cancer is unclear and warrants further studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40364-016-0064-5) contains supplementary material, which is available to authorized users. BioMed Central 2016-05-14 /pmc/articles/PMC4867989/ /pubmed/27186374 http://dx.doi.org/10.1186/s40364-016-0064-5 Text en © Borg et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Borg, David
Hedner, Charlotta
Gaber, Alexander
Nodin, Björn
Fristedt, Richard
Jirström, Karin
Eberhard, Jakob
Johnsson, Anders
Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
title Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
title_full Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
title_fullStr Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
title_full_unstemmed Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
title_short Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
title_sort expression of ifitm1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4867989/
https://www.ncbi.nlm.nih.gov/pubmed/27186374
http://dx.doi.org/10.1186/s40364-016-0064-5
work_keys_str_mv AT borgdavid expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma
AT hednercharlotta expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma
AT gaberalexander expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma
AT nodinbjorn expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma
AT fristedtrichard expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma
AT jirstromkarin expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma
AT eberhardjakob expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma
AT johnssonanders expressionofifitm1asaprognosticbiomarkerinresectedgastricandesophagealadenocarcinoma